human cardiomyocyte ac16 cell line (Millipore)
Structured Review

Human Cardiomyocyte Ac16 Cell Line, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cardiomyocyte ac16 cell line/product/Millipore
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Identifying and establishing the critical elements of a human cardiac in-vitro model for studying type-II diabetes"
Article Title: Identifying and establishing the critical elements of a human cardiac in-vitro model for studying type-II diabetes
Journal: Discover Applied Sciences
doi: 10.1007/s42452-025-07442-y
Figure Legend Snippet: Dose dependent effects of AGEs on AC16 cardiomyocytes. The varying doses applied included 100 µg, 250 and 500 µg for 24 h after which the cells were washed and replenished with complete growth medium. A live cell staining assay was performed to assess the effects of the varying doses of AGEs shown above. Scale bar indicates 100 μm
Techniques Used: Staining
Figure Legend Snippet: Expression Fold Change for gene expression of Cx-43 (encoded by GJA1) in AC16 cardiomyocytes after 48 h of AGEs exposure and post washouts. Data is represented as a normalized relative fold change to control. p-values between control and AGEs or AGEs washouts were significant (0.02) however in between AGEs and AGEs washout no significance was noted
Techniques Used: Expressing, Gene Expression, Control
Figure Legend Snippet: AC16 Cardiomyocytes Cardiac Myosin Heavy Chain (MHC) immunostaining for different experimental conditions: ( A ) Control, ( B ) AGEs, ( C ) Glucose Shock (50 mM), ( D ) AGEs followed by Glucose Shock, ( E ) Inhibitor followed by AGEs, ( F ) Inhibitor followed by AGEs and Glucose Shock. ( G ) Shows the expression levels of cardiac MHC calculated, data is represented as a normalized mean intensity to control. * Represents p < 0.05
Techniques Used: Immunostaining, Control, Expressing
Figure Legend Snippet: AC16 Cardiomyocytes Connexin 43 (Cx-43) immunostaining for different experimental conditions: ( A ) Control, ( B ) AGEs, ( C ) Glucose Shock (50 mM), ( D ) AGEs followed by Glucose Shock, ( E ) Inhibitor followed by AGEs, ( F ) Inhibitor followed by AGEs and Glucose Shock. ( G ) Shows the expression levels of Cx-43 calculated, data is represented as a normalized relative mean intensity to control. * Represents p < 0.05
Techniques Used: Immunostaining, Control, Expressing
Figure Legend Snippet: AC16 Cardiomyocytes RAGE expression for different experimental conditions: ( A ) Control, ( B ) AGEs (500 µg/ml), ( C ) Glucose Shock (50 mM), ( D ) AGEs followed by Glucose Shock, ( E ) Shows the expression levels of RAGE calculated, data is represented as a normalized relative mean intensity to DAPI. * Represents p < 0.05
Techniques Used: Expressing, Control
Figure Legend Snippet: Expression Fold Change for gene expression of Cx-43 (encoded by GJA1) in AC16 cardiomyocytes under different experimental conditions after 24 h of exposure. Data is represented as a normalized relative fold change to control. * Represents p < 0.05
Techniques Used: Expressing, Gene Expression, Control
Figure Legend Snippet: Dose dependent effects of AGEs on iCell Cardiomyocytes. The varying doses applied included ( A ) control, ( B ) 100 µg/ml, ( C ) 250 µg/ml, and ( D ) 500 µg/ml for 30 min after which the cells were washed and replenished with complete growth medium. ( E ) Shows the percentage cell viability measured from the live dead assay performed to assess the effects of the varying doses of AGEs.
Techniques Used: Control, Live Dead Assay
Figure Legend Snippet: Beat Rate heat maps and waveforms studied in relation with dose dependent effects of AGEs on iCell Cardiomyocytes. Image shows applied AGEs at a 100 µg/ml concentration for 30 min after which their contractility characterization was performed. Controls included wells with cells that did not receive any treatments and were washed and replenished with complete growth medium. The figure labels are as follows: ( A ) Control (Scale: 0 to 76), ( B ) AGEs (Scale: 0 to 56), ( C ) AGEs + Glucose Shock (Scale: 0 to 70), ( D ) AGEs Inhibitor + AGEs (Scale: 0 to 56), and ( E ) AGEs Inhibitor + AGEs 100 µg/ml + Glucose Shock (Scale: 0 to 70)
Techniques Used: Concentration Assay, Control
Figure Legend Snippet: Beat Rate heat maps and waveforms studied in relation with dose dependent effects of AGEs on iCell Cardiomyocytes. Image shows applied AGEs at a 250 µg/ml concentration for 30 min after which their contractility characterization was performed. Controls included wells with cells that did not receive any treatments and were washed and replenished with complete growth medium. The figure labels are as follows: ( A ) Control (Scale: 0 to 76), ( B ) AGEs (Scale: 0 to 42), ( C ) AGEs + Glucose Shock (Scale: 0 to 71), ( D ) AGEs Inhibitor + AGEs (Scale: 0 to 42), and ( E ) AGEs Inhibitor + AGEs 250 µg/ml + Glucose Shock (Scale: 0 to 71)
Techniques Used: Concentration Assay, Control
Figure Legend Snippet: Beats per minute (BPM) or cardiac contractile behavior studied in relation with dose dependent effects of AGES on iCell Cardiomyocytes. The varying doses applied included 100 and 250 µg/ml for 30 min after which they were recorded. Controls included wells with cells that did not receive any treatments and were washed and replenished with complete growth medium. * Represents p < 0.05
Techniques Used:
Figure Legend Snippet: iCell Cardiomyocytes control wells (no treatments): ( A ) Brightfield, ( B ) immunostaining and ( C ) RT-PCR of Cardiac MHC (encoded by MYH7)
Techniques Used: Control, Immunostaining, Reverse Transcription Polymerase Chain Reaction

